Prof. Boheng Zhang | Liver cancer | Best Researcher Award

Zhongshan Hospital, Fudan University | China

Author Profile

💼Professor Zhang Boheng 🎓🧬

Title:

Party Secretary and Executive Director of the Hepatocellular Carcinoma Department at Xiamen Hospital, affiliated with Zhongshan Hospital, Fudan University.

🎓Education and Training:

Doctor of Medicine (1996-1999): Fudan University
Master of Medicine (Clinical Epidemiology) (1992-1996): The University of Newcastle, Australia
Bachelor of Medicine (1983-1989): Fudan University School of Public Health
Advanced Training (2001-2002): Monash Medical School, Australia, and The Alfred Hospital

👨‍⚕️Professional Experience🏥:

Resident Physician (1989-1995): Zhongshan Hospital, Fudan University
Main Physician and Assistant Researcher (1995-2000): Zhongshan Hospital, Fudan University
Associate Researcher (2000-2009): Zhongshan Hospital, Fudan University
Doctoral Supervisor (2012-present): Zhongshan Hospital, Fudan University
Vice President and Executive Director (2017-2023): Hepatocellular Carcinoma Department, Xiamen Hospital
Party Secretary and Executive Director (2023-present): Hepatocellular Carcinoma Department, Xiamen Hospital

🏆Awards:

Standard Academic Contribution Award for Primary Liver Cancer in China (2024)
Top Ten Medical Contribution Experts of “Driving Forward the Industry” (2023)
Advanced Worker in Fujian Health System (2021)
Innovative Entrepreneur of Xiamen Special Economic Zone (2021), celebrating its 40th anniversary
Leading Talent in Medical Disciplines of Xiamen City, Fujian Province (2021)

📚Key Publications:

Early Detection of Cancer, co-edited with Yang Binghui, Fudan University Press, 2003
Liver Cancer in China, co-authored with Yang Binghui, in Screening for Common Malignancies: A Practical Guide, The Humana Press Inc., 2001
Clinical Epidemiology, co-edited, Jiangsu Science & Technology Press, 2018

🔬Research Projects:

Immunosuppressive Microenvironment in Intrahepatic Cholangiocarcinoma, National Natural Science Foundation of Fujian, 2022-2025, Principal Investigator
Precision Diagnosis and Treatment System for Hepatocellular Carcinoma, Key Science and Technology Project of Xiamen, 2019-2023
Innovation Project for High-Risk Hepatocellular Carcinoma Patients, Haicang District Health Bureau, Xiamen, ongoing
Effects of Shuangyouyin on Residual Cancer Cells Post-Chemotherapy, National Natural Science Foundation of China, 2010, Completed

🌐Professional Affiliations:

Chairman of the Sixth Committee, Evidence-Based Medicine Professional Committee, China Medical Association
Vice Chairman, Fifth Committee, Evidence-Based Medicine Professional Committee, China Medical Association
Member, Fifth Council, China Medical Association
Member, Eighth Committee, Clinical Epidemiology and Evidence-Based Medicine Branch, Chinese Medical Association
Vice Chairman, Shanghai Cancer Association Committee on Cancer Prevention and Screening

Prof. Zhang Boheng is a respected figure in oncology, dedicated to advancing liver cancer diagnostics, treatment, and prevention. His leadership in evidence-based medicine and clinical epidemiology supports his extensive work on hepatocellular carcinoma and contributes significantly to public health.

✨Conclusion:

Professor Zhang Boheng stands out as a prominent leader in the field of oncology, particularly in hepatocellular carcinoma research and treatment. His extensive education and training, coupled with decades of clinical and academic experience, have positioned him as an influential figure in advancing cancer care in China. Through his leadership roles and active participation in professional committees, he promotes evidence-based practices and innovative approaches in medicine.

Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)
- Authors: Zhou, J., Sun, H., Wang, Z., Dong, J., Fan, J.
- Journal: Liver Cancer
- Year: 2023

Development of the Scientific, Transparent and Applicable Rankings (STAR) tool for clinical practice guidelines
- Authors: Yang, N., Liu, H., Zhao, W., Chen, Y., Wei, J.
- Journal: Chinese Medical Journal
- Year: 2023

Tumor Radiomic Features on Pretreatment MRI to Predict Response to Lenvatinib plus an Anti-PD-1 Antibody in Advanced Hepatocellular Carcinoma: A Multicenter Study
- Authors: Xu, B., Dong, S.-Y., Bai, X.-L., Rao, S.-X., Sun, H.-C.
- Journal: Liver Cancer
- Year: 2023

A Novel Myeloid Cell Marker Genes Related Signature Can Indicate Immune Infiltration and Predict Prognosis of Hepatocellular Carcinoma: Integrated Analysis of Bulk and Single-Cell RNA Sequencing
- Authors: Zheng, S.-S., Wu, Y.-F., Zhang, B.-H., Huang, C., Xue, T.-C.
- Journal: Frontiers in Molecular Biosciences
- Year: 2023

Peripheral Lymphocytes in Primary Liver Cancers: Elevated NK and CD8+ T Cells and Dysregulated Selenium Metabolism
- Authors: Zhou, C., Lu, Z., Sun, B., Wang, Z., Qiu, S.-J.
- Journal: Biomolecules
- Year: 2024

📚 EARLY ACADEMIC PURSUITS

Professor Yibin Feng began his academic journey with a focus on traditional medicine and its applications in modern healthcare. His early studies laid a strong foundation in the integration of ancient practices with contemporary scientific research. His education likely included rigorous training in both the theoretical and practical aspects of herbal medicine, setting the stage for his future research.

🌟 PROFESSIONAL ENDEAVORS

Currently, Professor Feng is associated with The University of Hong Kong, where he specializes in liver cancer treatment using Chinese herbal formulas. His professional role involves leading research projects, mentoring students, and collaborating with other experts in the field to advance the understanding and application of traditional Chinese medicine in oncology.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON LIVER CANCER

Professor Feng’s research primarily concentrates on leveraging Chinese herbal formulas for treating liver cancer. His work explores how traditional remedies can be integrated into modern cancer treatments, aiming to enhance therapeutic outcomes and improve patient quality of life. His contributions include:

Investigating the efficacy of herbal formulas in liver cancer treatment.

Conducting clinical trials to validate the therapeutic potential of these traditional remedies.

Exploring the mechanisms through which these herbal treatments impact cancer cells and patient health.

🌍 IMPACT AND INFLUENCE

Professor Feng’s research has significantly influenced the field of integrative oncology. By bridging traditional Chinese medicine with modern cancer therapies, his work has opened new avenues for treatment strategies that blend ancient wisdom with cutting-edge science. His influence extends through:

Enhanced understanding of herbal medicine’s role in cancer treatment.

Development of new therapeutic approaches incorporating traditional remedies.

Increased acceptance and integration of alternative medicine in mainstream cancer care.

📈 ACADEMIC CITES

Professor Feng’s research is well-cited within the academic community, reflecting the impact and importance of his work. His publications contribute valuable insights into the application of herbal medicine in cancer treatment, and his findings are referenced by researchers and practitioners seeking to explore or validate similar approaches.

🏆 LEGACY AND FUTURE CONTRIBUTIONS

Professor Feng’s legacy is defined by his dedication to merging traditional and modern medical practices. His future contributions are expected to further advance the integration of Chinese herbal medicine into contemporary oncology, potentially leading to innovative treatments and improved patient outcomes. His ongoing research and collaborations will likely continue to shape the field and inspire future scholars and practitioners.

🌟 CONCLUSION

Professor Yibin Feng’s work exemplifies the successful integration of traditional Chinese herbal medicine with modern cancer treatment methodologies. His early academic pursuits laid a robust foundation for his current research, which focuses on leveraging herbal formulas to treat liver cancer. His professional endeavors at The University of Hong Kong underscore his commitment to advancing this field through innovative research and clinical applications.